Related Experiment Videos
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders
Insights
Chronic myeloproliferative disorders alter myelomonocytic progenitor cell populations. These changes in colony-forming unit granulocyte-macrophage (CFU-GM) type 1 and type 2 subpopulations differ significantly from normal subjects.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Myelomonocytic progenitors, specifically colony-forming unit granulocyte-macrophage (CFU-GM), play a crucial role in hematopoiesis.
- Chronic myeloproliferative disorders (MPNs) are a group of clonal hematopoietic stem cell diseases characterized by the overproduction of one or more myeloid lineages.
- Understanding the antigenic phenotype of progenitor cells in MPNs can provide insights into disease pathogenesis and potential therapeutic targets.
Purpose of the Study:
- To investigate the antigenic phenotype of myelomonocytic progenitors (CFU-GM) in patients with chronic myeloproliferative disorders.
- To identify and characterize subpopulations of CFU-GM (type 1 and type 2) using monoclonal antibodies.
- To compare the proportion and distribution of CFU-GM subpopulations in MPN patients with those in normal subjects.
Main Methods:
- Utilized four cytotoxic monoclonal antibodies to analyze CFU-GM from 33 patients with MPNs.
- Identified two myelomonocytic progenitor subpopulations (type 1 and type 2 CFU-GM) using the R1B-19 antibody.
- Quantified the proportions of type 1 and type 2 CFU-GM in bone marrow and peripheral blood samples.
Main Results:
- Monoclonal antibodies S3-13, S8-6, and S16-144 reacted with most CFU-GM, indicating conserved antigen expression.
- A higher proportion of immature type 1 CFU-GM was observed in bone marrow of patients with chronic myelogenous leukemia, chronic myelomonocytic leukemia, and polycythemia vera.
- The differentiated type 2 CFU-GM, absent in normal peripheral blood, was present in high proportions in peripheral blood of patients with chronic myelogenous leukemia, chronic myelomonocytic leukemia, and idiopathic myelofibrosis.
Conclusions:
- Antigens on normal CFU-GM are expressed in chronic myeloproliferative disorders.
- The proportion and distribution of type 1 and type 2 CFU-GM are significantly altered in MPNs compared to normal individuals.
- These findings highlight distinct progenitor cell profiles in MPNs, suggesting potential diagnostic or prognostic value.
Abstract:
The antigenic phenotype of myelomonocytic progenitors [colony-forming unit granulocyte-macrophage (CFU-GM)] from 33 patients with chronic myeloproliferative disorders was investigated using four cytotoxic monoclonal antibodies. Monoclonal antibodies S3-13, S8-6, and S16-144 which recognize normal hemopoietic progenitors of different lineages reacted with almost all CFU-GM. R1B-19 monoclonal antibody identified two subpopulations of myelomonocytic progenitors (type 1 and 2 CFU-GM), as reported previously in normal subjects. In 3 of 11 patients with chronic myelogenous leukemia, in 1 of 2 patients with chronic myelomonocytic leukemia, and in 2 of 4 patients with polycythemia vera, a higher proportion of the more immature CFU-GM (type 1) was detected in bone marrow cells. The more differentiated CFU-GM (type 2) is not detectable in normal peripheral blood. By contrast, in 14 of 15 chronic myelogenous leukemia patients, in 1 of 2 chronic myelomonocytic leukemia patients and in 3 of 8 patients with idiopathic myelofibrosis, it was present in high to very high proportions. It is clear from these findings that the antigens present on normal CFU-GM are expressed in chronic myeloproliferative disorders. The proportion and distribution of type 1 and 2 CFU-GM, on the other hand, are very different from those observed in the normal subjects.